Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. Show more

Location: Australia Square, L 12 95 Pitt St, Sydney, NSW, 2000, Australia | Website: https://www.immutep.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

237.3M

52 Wk Range

$1.32 - $2.72

Previous Close

$1.63

Open

$1.66

Volume

143,435

Day Range

$1.59 - $1.67

Enterprise Value

144.2M

Cash

129.7M

Avg Qtr Burn

-15.51M

Insider Ownership

0.01%

Institutional Own.

1.91%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Phase 2/3

Data readout

Eftilagimod Alpha (LAG-3lg or IMP321) + Keytruda Details
Head and neck squamous cell carcinoma (1L HNSCC)

Phase 2b

Update

Phase 2

Update

Phase 1

Data readout

Phase 1

Data readout

Phase 1

Update

Failed

Discontinued